UNSPSC 51343505: Adefovir pivoxil

This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H32N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6Q8Z01514, chemically known as adefovir di(pivaloyloxymethyl) ester [mi], but more generally known as adefovir pivoxil, which bears US NIH Compound Identifier 60871. European Medicines Agency schedules adefovir pivoxil or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05264MIG.

Most nations, for tariff purposes, schedule adefovir pivoxil under HS 29335995. SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1CNC2C1NCNC2N)OCOC(=O)C(C)(C)C.

UNSPSC 51343505 Adefovir pivoxil is a Commodity code that nominally identifies a specific antiviral pharmaceutical, but recent state and local solicitations tagged under this code show minimal or no direct alignment with adefovir itself. Instead, the opportunities posted under this code span a broader range of pharmaceutical procurement — from emergency naloxone and drug deactivation systems, to direct-to-manufacturer prescription program design, to generic multi-source pharmaceuticals and over-the-counter products, to medical and first aid supplies for emergency responders. This divergence suggests the code may function as a catch-all pharmaceutical or medical-supply category in some jurisdictions' procurement systems, rather than a specific-drug code. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal purchasing departments (City of Tampa Fire Department), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The geographic spread spans Florida, Texas, Minnesota, and Oregon, with no single state dominating recent activity.

Recent representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023, with estimated quarterly deliveries to a county health building; the Texas HHS Commission's Request for Information regarding direct-to-manufacturer prescription programs, due April 3, 2026, to inform future pharmacy benefit contracting; the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000 and a 5 percent small local business enterprise discount set-aside; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026 and distribution through three authorized wholesalers. The code shows activity across different procurement instruments — IFBs, RFQs, RFIs, and RFPs — reflecting the varied procurement approaches state and local agencies use for pharmaceutical and medical-supply buys.